BioTuesdays

Category - Markets

ARS-Pharma-Logo
Markets

SVB starts ARS Pharma at OP; PT $14

SVB Securities launched coverage of ARS Pharmaceuticals (NASDAQ:SPRY) with an “outperform” rating and $14 price target. The stock closed at $7.12 on Dec. 12. ARS is developing neffy, an intranasal epinephrine product in...

December 13, 2022
Pardes Biosciences Logo
Markets

JMP starts Pardes Biosciences at MO; PT $9

JMP Securities initiated coverage of Pardes Biosciences (NASDAQ:PRDS) with a “market outperform” rating and price target of $9. The stock closed at $1.15 on Dec. 12. Pardes is developing PBI-0451 as a potential novel...

December 13, 2022
Affimed Logo
Markets

HCW starts Affimed at buy; PT $6

H.C. Wainwright launched coverage of Affimed NV (NASDAQ:AFMD) with a “buy” rating and $6 price target. The stock closed at $2.04 on Dec. 9. Affimed is a clinical-stage biotechnology company focused on developing innate...

December 12, 2022
Enanta Logo
Markets

HCW starts Enanta Pharma at buy; PT $56

H.C. Wainwright initiated coverage of Enanta Pharmaceuticals (NASDAQ:ENTA) with a “buy” rating and $56 price target. The stock closed at $41.78 on Dec. 8. Enanta’s claim to fame is the discovery of glecaprevir...

December 9, 2022
Opthea Logo
Markets

HCW starts Opthea at buy; PT $14

H.C. Wainwright launched coverage of Opthea (NASDAQ:OPT) with a “buy” rating and $14 price target. The stock closed at $4.97 on Dec. 7. Opthea is focused on patients suffering from retinal eye diseases, such as wet age...

December 8, 2022
Blue Water Vaccines Logo
Markets

Maxim starts Blue Water Vaccines at buy; PT $4

Maxim Group initiated coverage of Blue Water Vaccines (NASDAQ:BWV) with a “buy” rating and price target of $4. The stock closed at $1.15 on Dec. 7. Blue Water is developing a portfolio of vaccine candidates targeting...

December 8, 2022
Aerovate Therapeutics
Markets

BTIG ups Aerovate to buy on competitor data

BTIG upgraded Aerovate Therapeutics (NASDAQ:AVTE) to “buy” from “neutral” with a $27 price target, citing Gossamer Bio’s TORREY results that could validate Aerovate’s dry powder inhalation (DPI) administered tyrosine...

December 6, 2022
ImmunoPrecise Logo
Markets

HCW starts ImmunoPrecise Antibodies at buy; PT $9

H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies (NASDAQ:IPA) with a “buy” rating and price target of $9. The stock closed at $4.93 on Dec. 1. ImmunoPrecise is a contract research organization (CRO) that...

December 2, 2022